ATE352613T1 - Chimäres tier und methode zu dessen herstellung - Google Patents

Chimäres tier und methode zu dessen herstellung

Info

Publication number
ATE352613T1
ATE352613T1 AT96928694T AT96928694T ATE352613T1 AT E352613 T1 ATE352613 T1 AT E352613T1 AT 96928694 T AT96928694 T AT 96928694T AT 96928694 T AT96928694 T AT 96928694T AT E352613 T1 ATE352613 T1 AT E352613T1
Authority
AT
Austria
Prior art keywords
same
fragment
producing same
chimeric animal
producing
Prior art date
Application number
AT96928694T
Other languages
English (en)
Inventor
Kazuma Tomizuka
Hitoshi Yoshida
Kenkyusho Gijutsu
Kazunori Hanaoka
Mitsuo Oshimura
Isao Ishida
Kanazawa-Ku Fukuura
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of ATE352613T1 publication Critical patent/ATE352613T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96928694T 1995-08-29 1996-08-29 Chimäres tier und methode zu dessen herstellung ATE352613T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24234095 1995-08-29
JP2794096 1996-02-15

Publications (1)

Publication Number Publication Date
ATE352613T1 true ATE352613T1 (de) 2007-02-15

Family

ID=26365944

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928694T ATE352613T1 (de) 1995-08-29 1996-08-29 Chimäres tier und methode zu dessen herstellung

Country Status (11)

Country Link
EP (3) EP0773288A3 (de)
JP (1) JP4318736B2 (de)
KR (1) KR100308764B1 (de)
CN (2) CN101333516A (de)
AT (1) ATE352613T1 (de)
AU (1) AU718138B2 (de)
CA (1) CA2230759C (de)
DE (1) DE69636868T2 (de)
DK (1) DK0843961T3 (de)
TW (1) TW448032B (de)
WO (1) WO1997007671A1 (de)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908127D0 (en) * 1989-04-11 1989-05-24 Shaw Francis & Co Ltd Mixer and a method of a mixer control
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
DE69841452D1 (de) * 1997-02-28 2010-03-04 Kyowa Hakko Kirin Co Ltd Humanes Chromosomfragment und ein Vektor, der dies enthält
WO1998046733A1 (en) * 1997-04-11 1998-10-22 Imperial College Of Science Technology And Medicine Chromosome transfer (xmmct) to es cells, induced during the exposure of microcells to radiation
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
JP4689781B2 (ja) * 1998-09-03 2011-05-25 独立行政法人科学技術振興機構 アミノ酸輸送蛋白及びその遺伝子
DK2314315T3 (en) 1999-06-01 2015-02-02 Biogen Idec Inc Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU6476000A (en) * 1999-08-13 2001-03-13 Kirin Beer Kabushiki Kaisha Mouse having human cytochrome p450 transferred therein
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US7414170B2 (en) 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7074983B2 (en) 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
US7820878B2 (en) 1999-11-19 2010-10-26 Kyowa Hakko Kirin Co., Ltd. Production of ungulates, preferably bovines that produce human immunoglobulins
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
WO2001077357A2 (en) * 2000-04-07 2001-10-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Chromosomal vectors and uses thereof
DE60144305D1 (de) 2000-11-17 2011-05-05 Kyowa Hakko Kirin Co Ltd Expression von xenogenen (humanen) Immunglobulinen in klonierten, transgenen Huftieren
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
AU2002246733B2 (en) * 2000-12-19 2007-09-20 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
MXPA03009390A (es) 2001-04-13 2004-01-29 Biogen Inc Anticuerpos para integrina vla-1.
JP2002316944A (ja) * 2001-04-17 2002-10-31 Chemo Sero Therapeut Res Inst ヒトポリクローナル抗体組成物
CN1789416B (zh) 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
JP4087338B2 (ja) * 2001-11-15 2008-05-21 キリンファーマ株式会社 キメラ非ヒト動物
EP2110434A1 (de) 2002-02-25 2009-10-21 Genentech, Inc. Typ-1 Cytokine Rezeptor GLM-R
MXPA04008870A (es) 2002-03-13 2005-06-17 Biogen Idec Inc Anticuerpos anti-avb6.
IL164287A0 (en) 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
DE60332111D1 (de) * 2002-05-17 2010-05-27 Kyowa Hakko Kirin Co Ltd Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind
EP2206517B1 (de) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
ME00204B (me) * 2002-09-06 2011-02-10 Medarex Llc Terapijsko, humano, monoklonsko anti-il-1r1antitijelo
JP2006505291A (ja) 2002-11-08 2006-02-16 ヘマテック，エルエルシー プリオンタンパク質活性が低減されたトランスジェニック有蹄動物及びその用途
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
KR20120090094A (ko) 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 아글리코실 항-ｃｄ154(ｃｄ40 리간드) 항체 및 이의 용도
CA2530172A1 (en) 2003-06-27 2005-02-10 Abgenix, Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
CA2535156A1 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
EP1533617A1 (de) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
SI2177537T1 (sl) 2004-01-09 2012-01-31 Pfizer Protitielesa proti MAdCAM
AU2005227313A1 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through V gene manipulation
CA2563064A1 (en) 2004-04-22 2005-11-10 Kirin Beer Kabushiki Kaisha Transgenic animals and uses thereof
EP2399936A3 (de) 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anti-CD154-Antikörper
CA2958259C (en) 2004-10-22 2020-06-30 Revivicor, Inc. Ungulates with genetically modified immune systems
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
WO2006068975A2 (en) 2004-12-20 2006-06-29 Abgenix, Inc. Binding proteins specific for human matriptase
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
DE602006019977D1 (de) 2005-08-18 2011-03-17 Genmab As Therapie mit anti-cd4-antikörpern und bestrahlung
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
AU2006321593B2 (en) 2005-12-07 2012-10-04 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens
DK1979001T3 (da) 2005-12-13 2012-07-16 Medimmune Ltd Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
LT2481753T (lt) 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
EP1962903B1 (de) 2005-12-15 2013-03-13 MedImmune Limited Kombination eines angiopoetin-2-antagonisten und eines vegf-a, kdr- und/oder fltl-antagonisten zur behandlung von krebs
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2004228A1 (de) * 2006-02-28 2008-12-24 Oncotherapy Science, Inc. Verfahren zur schädigung von zellen mit effektor-funktionen von anti-epha4-antikörpern
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2839843B1 (de) 2006-05-25 2018-06-20 Biogen MA Inc. VLA-1-Antagonisten zur Verwendung bei der Behandlung von Schlaganfall
JP5345391B2 (ja) 2006-07-07 2013-11-20 協和発酵キリン株式会社 ヒト人工染色体（ｈａｃ）ベクター及びヒト人工染色体（ｈａｃ）ベクターを有するヒト細胞医薬
CN101563105B (zh) 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 用于抑制smad4-缺陷癌症的组合物和方法
EP2064244B1 (de) 2006-08-03 2019-06-05 MedImmune Limited GEGEN alphaVbeta6 GERICHTETE ANTIKÖRPER UND IHRE VERWENDUNG
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CA2663243A1 (en) 2006-09-28 2008-04-03 Merck Serono S.A. Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
JP2010521670A (ja) 2007-03-12 2010-06-24 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド Ｆａｎｃｉおよびｆａｎｃｉを調整する薬剤の予後での、診断での、および癌治療での使用
EP2125894B1 (de) 2007-03-22 2018-12-19 Biogen MA Inc. Bindungsproteine mit antikörpern, antikörperderivaten und antikörperfragmenten mit spezifischer bindung an cd154 sowie ihre verwendung
EP2006304A1 (de) * 2007-06-22 2008-12-24 Stiftung Für Diagnostische Forschung Monokloner Antikörper gegen HPA-5b
WO2009054873A2 (en) 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
EP2615114B1 (de) 2007-08-23 2022-04-06 Amgen Inc. Antigenbindende Proteine an Proprotein-Konvertase-Subtilisin/Kexin vom Typ 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
SI2207809T1 (sl) 2007-09-26 2013-11-29 U3 Pharma Gmbh Proteini, ki veĹľejo antigen rastnega faktorja, podobnega epidermalnemu rastnemu faktorju, ki veĹľe heparin
CA2700860C (en) * 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
GB0720552D0 (en) * 2007-10-19 2007-11-28 Iti Scotland Ltd Multiple cluster knockout
CN101939336B (zh) 2007-11-12 2014-05-14 U3制药有限公司 Axl抗体
EP2344536A1 (de) 2008-09-19 2011-07-20 MedImmune, LLC Gegen dll4 gerichtete antikörper und anwendungen davon
ES2548377T3 (es) 2008-10-27 2015-10-16 Revivicor, Inc. Ungulados inmunodeprimidos
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
US8137671B2 (en) 2009-05-05 2012-03-20 Genentech, Inc. Anti-IL-17F antibodies
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
NZ600002A (en) * 2009-11-17 2014-08-29 Sanford Applied Biosciences L L C Human artificial chromosome vector
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
JP2013540694A (ja) 2010-08-06 2013-11-07 ウー３・フアルマ・ゲー・エム・ベー・ハー Ｈｅｒ３結合剤の前立腺治療における使用
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
WO2013067054A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EA201490974A1 (ru) 2011-11-16 2014-09-30 Эмджен Инк. СПОСОБЫ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С ДЕЛЕЦИОННЫМ МУТАНТОМ vIII ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
JP6133544B2 (ja) * 2012-03-16 2017-05-24 康宏 香月 ミクロセル保存方法
SMT201800395T1 (it) 2012-03-16 2018-09-13 Regeneron Pharma Anticorpi a catena leggera ingegnerizzati con istidina e roditori modificati geneticamente per la generazione degli stessi
PT2825037T (pt) 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
CN103387955B (zh) * 2012-05-10 2015-04-29 上海南方模式生物科技发展有限公司 非人哺乳动物b淋巴细胞缺陷动物模型的制备方法及其用途
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
WO2014123580A1 (en) 2013-02-06 2014-08-14 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
SI2970449T1 (sl) 2013-03-15 2019-11-29 Amgen Res Munich Gmbh Enoverižne vezavne molekule, ki vsebujejo N-terminalni ABP
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
WO2014209384A1 (en) 2013-06-28 2014-12-31 Amgen Inc. Methods for treating homozygous familial hypercholesterolema
US10077304B2 (en) 2013-08-14 2018-09-18 The Governing Council Of The University Of Toronto Antibodies against frizzled receptor
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
WO2015167011A1 (ja) 2014-05-02 2015-11-05 株式会社カイオム・バイオサイエンス ヒト抗体を産生する細胞
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
MX384418B (es) 2014-07-31 2025-03-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
EP3191126B1 (de) 2014-09-13 2020-05-13 Novartis AG Kombinationstherapien aus alk-hemmern
TWI772258B (zh) 2015-04-17 2022-08-01 德商安美基研究（慕尼黑）公司 Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TN2018000266A1 (en) 2016-02-03 2020-01-16 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
IL313507A (en) 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
AU2017234163B2 (en) 2016-03-15 2023-01-19 Mersana Therapeutics, Inc. NaPi2b-targeted antibody-drug conjugates and methods of use thereof
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
EP3432925A4 (de) 2016-03-22 2019-11-06 Bionomics Limited Verabreichung eines monoklonalen anti-lgr5-antikörpers
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
CN109906272A (zh) * 2016-10-31 2019-06-18 国立大学法人鸟取大学 产生人抗体的非人动物和使用该非人动物的人抗体制作方法
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
AU2018261951B2 (en) 2017-05-05 2025-05-22 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
CN109136261B (zh) 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化cd28基因改造动物模型的制备方法及应用
WO2018233608A1 (en) * 2017-06-19 2018-12-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric cd28
CR20200076A (es) 2017-07-14 2020-06-10 Pfizer ANTICUERPOS CONTRA MAdCAM
CN109837307B (zh) * 2017-11-24 2023-09-19 中国科学院脑科学与智能技术卓越创新中心 建立含外源染色体的胚胎干细胞的方法
TWI827570B (zh) 2017-12-11 2024-01-01 美商安進公司 雙特異性抗體產品之連續製造製程
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
MX2021001221A (es) 2018-07-30 2021-06-23 Amgen Res Munich Gmbh Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
IL280467B2 (en) 2018-08-03 2025-03-01 Amgen Res Munich Gmbh Antibody constructs for CLDN18.2 and CD3
ES2980115T3 (es) 2018-08-27 2024-09-30 Affimed Gmbh Células NK crioconservadas precargadas con una construcción de anticuerpo
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2020169022A1 (en) 2019-02-18 2020-08-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animals with humanized immunoglobulin locus
EP3983520A1 (de) 2019-06-13 2022-04-20 Amgen, Inc Automatisierte biomassebasierte perfusionssteuerung zur herstellung von biologika
AU2020323901A1 (en) 2019-07-26 2022-02-24 Amgen Inc. Anti-IL13 antigen binding proteins
CA3152946A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
EP4058485A1 (de) 2019-11-13 2022-09-21 Amgen Inc. Verfahren zur verringerung der aggregatbildung bei der nachgelagerten verarbeitung von bispezifischen antigen-bindenden molekülen
AU2020405230A1 (en) 2019-12-20 2022-06-23 Amgen Inc. Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
WO2021130383A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
EP4118113A1 (de) 2020-03-12 2023-01-18 Amgen Inc. Verfahren zur behandlung und prophylaxe von crs bei patienten mit einer kombination aus bispezifischen antikörpern zur bindung an cds x-krebszellen und tnfalpha- oder il-6-hemmer
CA3175275A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
EP4153633A1 (de) 2020-05-19 2023-03-29 Amgen Inc. Mageb2-bindende konstrukte
IL298632A (en) 2020-06-02 2023-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Non-human animals genetically modified with a common light chain immunoglobulin locus
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
CN116323671A (zh) 2020-11-06 2023-06-23 安进公司 具有增加的选择性的多靶向性双特异性抗原结合分子
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
MX2023005197A (es) 2020-11-06 2023-05-16 Amgen Inc Dominio de union a antigeno con tasa de recorte reducida.
EP4240767A1 (de) 2020-11-06 2023-09-13 Amgen Inc. An cd3 bindende polypeptidkonstrukte
EP4314078A1 (de) 2021-04-02 2024-02-07 Amgen Inc. Mageb2-bindende konstrukte
US20240384006A1 (en) 2021-05-06 2024-11-21 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
MX2024005397A (es) 2021-11-03 2024-05-23 Affimed Gmbh Agentes de union a cd16a biespecificos.
US20240392313A1 (en) 2021-11-16 2024-11-28 National University Corporation Tottori University Mammalian artificial chromosome vector having human immunoglobulin heavy chain locus comprising modified d-region, and cell or non-human animal retaining the vector
EP4522651A1 (de) 2022-05-12 2025-03-19 Amgen Research (Munich) GmbH Mehrkettige, multitargeting, bispezifische antigenbindende moleküle mit erhöhter selektivität
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
AU2024302269A1 (en) 2023-06-14 2025-11-13 Amgen Inc. T cell engager masking molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA874410B (en) * 1986-06-24 1988-04-27 Merrell Dow Pharma Fusion products

Also Published As

Publication number Publication date
CN1200014A (zh) 1998-11-25
EP0773288A2 (de) 1997-05-14
CA2230759C (en) 2012-02-21
JP4318736B2 (ja) 2009-08-26
DE69636868D1 (de) 2007-03-15
KR19990044300A (ko) 1999-06-25
EP0843961A4 (de) 2000-08-09
CA2230759A1 (en) 1997-03-06
TW448032B (en) 2001-08-01
JP2008200042A (ja) 2008-09-04
CN101333516A (zh) 2008-12-31
AU6837696A (en) 1997-03-19
WO1997007671A1 (en) 1997-03-06
AU718138B2 (en) 2000-04-06
EP1916300A1 (de) 2008-04-30
EP0843961B1 (de) 2007-01-24
DK0843961T3 (da) 2007-05-21
CN100379857C (zh) 2008-04-09
EP0773288A3 (de) 1997-07-09
EP0843961A1 (de) 1998-05-27
DE69636868T2 (de) 2007-10-25
KR100308764B1 (ko) 2001-12-17
HK1008472A1 (en) 1999-11-12

Similar Documents

Publication Publication Date Title
ATE352613T1 (de) Chimäres tier und methode zu dessen herstellung
DK0972445T3 (da) Kimærisk mus som udtrykker et humant antistof
AU1595195A (en) Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals
ES2074999T3 (es) Plantas de zea mays y plantas de zea mays transgenicas regeneradas de protoplastos o celulas derivadas de protoplastos.
DE69939744D1 (de) Verfahren zur herstellung stresstoleranter pflanzen
EP1017423A4 (de) Klonieren von Schweinen unter Verwendung von Donorzellkernen aus differenzierten Zellen
DE3856446D1 (de) Alpha-amidierende Enzymzusammensetzungen und Verfahren zu deren Herstellung und Verwendung
DK1085083T3 (da) Dyrkningsmedium for dyreceller og fremgangsmåde til proteinfremstilling under anvendelse af dette
DE69637631D1 (de) Künstliche säuger chromosome
EP0270615A4 (de) TRANSFORMATION UND EXPRESSION EINES FREMDEN GENS IN -i(BRASSICA) SPEZIES.
EP0474790A4 (en) Media for cell growth and method for making them
EP1019491A4 (de) Herstellung embryonischer vogel keimzellinien durch verlängerte kultivierung von pgcs, verwendung desselben zur klonierung und chimerisierung
DE59712068D1 (de) Verfahren zur herstellung von säugetieren mit definierten genetischen eigenschaften
DE60027570D1 (de) Verfahren zur herstellung künstlicher pflanzenchromosomen
IT1216140B (it) Procedimento per preparare alghe aventi effetti biologici migliorati.
DK326788A (da) Fremgangsmaade til fremstilling af en cellelinje
EP2281892A3 (de) Verfahren zur Herstellung von Polypeptiden in atmungsdefizienten Trichoderma Zellen
WO2000068371A8 (fr) Procede de culture cellulaire
ATE313638T1 (de) Produktion von genetisch geänderten pflanzen mit püroindoline
EP0987324A3 (de) Zellwachstumsbeschleunigungsmittel enthaltende Polyphosphorsäure und Zellwachstumsmethode
DE68906071D1 (de) Methode zur herstellung einer gasdicht verschlossenen elektrochemischen zelle.
DK1238057T3 (da) Fremgangsmåde til produktion af vedhæftende dyreceller
CA2284133A1 (en) Novel cell line and screening method with the use of the same
HK1039744A1 (zh) 刺激prosaposin受体活性的方法
NO902039L (no) Fremgangsmaate ved dyrking av cellekulturer i bioreaktor.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties